Olema Pharmaceuticals, Inc. (OLMA)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$52.6M
Cash & Equivalents
$46.0M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$1,128M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT05508906 Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, ... PHASE1 Recruiting 190

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for OLMA.

SEC EDGAR Filings

All SEC filings for Olema Pharmaceuticals, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.